ARS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.83 USD | -3.92% |
|
-1.67% | +61.13% |
Presenter SpeechUnknown Analyst (Analysts)Hello, and welcome, everyone. Thank you for joining ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Calendar
2024-06-20
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.19
USD
Average target price
19
USD
Spread / Average Target
+106.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.13% | 890M | |
| +44.48% | 54.04B | |
| +43.57% | 41.96B | |
| -0.86% | 41.92B | |
| -7.59% | 28.35B | |
| +12.30% | 26.35B | |
| -21.83% | 19B | |
| +7.15% | 13B | |
| +29.40% | 12.28B | |
| +25.15% | 12.19B |
- Stock Market
- Equities
- SPRY Stock
- News ARS Pharmaceuticals, Inc.
- Transcript : Silverback Therapeutics, Inc. Presents at H.C. Wainwright BioConnect Conference, Jan-10-2022 07
